Cargando…
Effects of Structurally Different HDAC Inhibitors against Trypanosoma cruzi, Leishmania, and Schistosoma mansoni
[Image: see text] Neglected tropical diseases (NTDs), including trypanosomiasis, leishmaniasis, and schistosomiasis, result in a significant burden in terms of morbidity and mortality worldwide every year. Current antiparasitic drugs suffer from several limitations such as toxicity, no efficacy towa...
Autores principales: | Di Bello, Elisabetta, Noce, Beatrice, Fioravanti, Rossella, Zwergel, Clemens, Valente, Sergio, Rotili, Dante, Fianco, Giulia, Trisciuoglio, Daniela, Mourão, Marina M., Sales, Policarpo, Lamotte, Suzanne, Prina, Eric, Späth, Gerald F., Häberli, Cécile, Keiser, Jennifer, Mai, Antonello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274761/ https://www.ncbi.nlm.nih.gov/pubmed/35732073 http://dx.doi.org/10.1021/acsinfecdis.2c00232 |
Ejemplares similares
-
Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth
por: Chua, Ming Jang, et al.
Publicado: (2016) -
Modulation of
Host–Parasite Interactions with
Small Molecules Targeting Schistosoma mansoni microRNAs
por: Hamway, Youssef, et al.
Publicado: (2022) -
Naturally Occurring Cardenolides Affecting Schistosoma mansoni
por: Keiser, Jennifer, et al.
Publicado: (2020) -
Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni
por: Cowan, Noemi, et al.
Publicado: (2015) -
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
por: Panic, Gordana, et al.
Publicado: (2015)